Cargando…

Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring

BACKGROUND: Determination of programmed death-ligand 1 (PD-L1) protein expression level in tumor cells and tumor-associated immune cells is critical for identifying patients eligible for immunotherapy. PD-L1 manual scoring algorithms can generally be divided into two categories: cell counting and vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chunyan, Fang, Fang, Kong, Ying, ElGabry, Ehab A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114344/ https://www.ncbi.nlm.nih.gov/pubmed/37076889 http://dx.doi.org/10.1186/s13000-023-01318-8

Ejemplares similares

Programmed Cell Death Ligand 1 Pathologist Training in the Time of COVID-19: Our Experience using a Digital Solution
por: Hayden, Dorothy, et al.
Publicado: (2021)

Frequency and characterization of celiac ganglia diagnosed on fine-needle aspiration
por: ElGabry, Ehab A., et al.
Publicado: (2015)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
por: Jasani, Bharat, et al.
Publicado: (2020)

Association of the programmed death ligand‐1 combined positive score in tumors and clinicopathological features in esophageal cancer
por: Huang, Ziling, et al.
Publicado: (2021)

Combined Positive Score for Programmed Death Ligand-1 Expression and Inflammatory Microenvironment in Gastrointestinal Stromal Tumors
por: Herlea, Vlad, et al.
Publicado: (2022)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
por: Ricci, Costantino, et al.
Publicado: (2020)

Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors
por: Chovanec, Michal, et al.
Publicado: (2017)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
por: Zhou, Jiandong, et al.
Publicado: (2022)

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
por: Mei, Yu, et al.
Publicado: (2016)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
por: Witte, Hanno M., et al.
Publicado: (2020)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

MON-287 Expression of Programmed Death-Ligand 1 (PD-L1) in Human Pituitary Neuroendocrine Tumor
por: Suteau, Valentine, et al.
Publicado: (2020)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
por: Cho, Yoon Ah, et al.
Publicado: (2021)

Tapping Ovarian Tumors
por: Wright, M. B.
Publicado: (1876)

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
por: Anantharaman, Archana, et al.
Publicado: (2016)

Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
por: Rom-Jurek, Eva-Maria, et al.
Publicado: (2018)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer
por: Yan, Rong, et al.
Publicado: (2019)

Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells
por: Cruz-Rico, Graciela, et al.
Publicado: (2021)

Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists
por: Lang-Schwarz, Corinna, et al.
Publicado: (2021)

Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
por: Mercier, Anaïs, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
por: Park, Seongho, et al.
Publicado: (2019)

Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
por: Liu, Jingxin, et al.
Publicado: (2021)

Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
por: Asanuma, Kunihiro, et al.
Publicado: (2020)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer
por: Kwantwi, Louis Boafo, et al.
Publicado: (2021)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Programmed Death-ligand 1 (PD-L1) Expression in Bladder Cancer and its Correlation with Tumor Grade, Stage, and Outcome
por: Al Nabhani, Safia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_90vb4vc22ifu343244ocrk82jg